GT BIOPHARMA, INC. Proceeds from Issuance of Medium-term Notes
GT BIOPHARMA, INC. (GTBP) reported Proceeds from Issuance of Medium-term Notes of $1.21 million for the 12-month period ending 2021-12-31, per its 10-K filed 2023-03-30.
Discontinued › Cash Flow › Financing Activities
us-gaap:ProceedsFromIssuanceOfMediumTermNotes · last filed 2023-03-30
- GT BIOPHARMA, INC. proceeds from issuance of medium-term notes for the quarter ending 2021-03-31 was $1.21M.
- GT BIOPHARMA, INC. proceeds from issuance of medium-term notes for fiscal 2021 was $1.21M, a 90.38% decline from fiscal 2020.
- GT BIOPHARMA, INC. proceeds from issuance of medium-term notes for fiscal 2020 was $12.53M.
| Period end | Proceeds from Issuance of Medium-term Notes 3 month | Proceeds from Issuance of Medium-term Notes 6 month | Proceeds from Issuance of Medium-term Notes 9 month | Proceeds from Issuance of Medium-term Notes 12 month |
|---|---|---|---|---|
| 2021-12-31 | $1.21M 10-K · filed 2023-03-30 | |||
| 2021-09-30 | $1.21M 10-Q · filed 2022-10-31 | |||
| 2021-06-30 | $1.21M 10-Q · filed 2022-08-15 | |||
| 2021-03-31 | $1.21M 10-Q · filed 2022-05-16 | |||
| 2020-12-31 | $12.53M 10-K · filed 2022-03-28 | |||
| 2020-09-30 | $5.66M 10-Q · filed 2021-11-10 | |||
| 2020-06-30 | $4.46M 10-Q/A · filed 2021-12-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |